Clinical trial explores new therapeutic for type 1 diabetes

(Medical University of South Carolina) MUSC researchers launch the first NIH-funded clinical trial in the United States using umbilical cord derived mesenchymal stem cells for the treatment of patients with new onset type 1 diabetes.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Conclusion A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSIONS: Our data show that human iPSC-derived beta cells respond to pro-inflammatory cytokines IL-1β + IFNγ and IFNα, by activating the same pathogenic processes as adult human primary beta cells. These cells thus represent a valuable tool for future research on the pathogenesis of type 1 diabetes. PMID: 31900242 [PubMed - in process]
Source: Cell Research - Category: Cytology Authors: Tags: Stem Cell Res Ther Source Type: research
Conclusion A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all...
Source: Fight Aging! - Category: Research Authors: Tags: Of Interest Source Type: blogs
Publication date: Available online 12 December 2019Source: Stem Cell ReportsAuthor(s): Aaron A. Stock, Vita Manzoli, Teresa De Toni, Maria M. Abreu, Yeh-Chuin Poh, Lillian Ye, Adam Roose, Felicia W. Pagliuca, Chris Thanos, Camillo Ricordi, Alice A. TomeiSummaryThe scarcity of donors and need for immunosuppression limit pancreatic islet transplantation to a few patients with labile type 1 diabetes. Transplantation of encapsulated stem cell-derived islets (SC islets) might extend the applicability of islet transplantation to a larger cohort of patients. Transplantation of conformal-coated islets into a confined well-vascular...
Source: Stem Cell Reports - Category: Stem Cells Source Type: research
Abstract Physiologically sufficient β cell regeneration can be achieved by the induction of hematopoietic chimerism in a type 1 diabetes mellitus (T1DM) mouse model. However, pancytopenia and graft-versus-host disease (GVHD) limits the clinical adaptation of this modality. In this review, we discuss new perceptions on the induction of chimerism, without bone marrow (BM) recipient conditioning, via supplementation of mesenchymal stem cells (MSCs) to support engraftment of allogeneic HSCs. The use of haploidentical, gender-matched, predisposing T1DM genotype-free HSCs in combination with MHC-disparate MSCs coul...
Source: Drug Discovery Today - Category: Drugs & Pharmacology Authors: Tags: Drug Discov Today Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Researchers believe they may help restore normal immune function in adults with type 1 disease with injections of stem cells, enabling the pancreas to produce insulin.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
W.L. Gore &Associates is setting its sights on helping to improve insulin therapy in patients with type 1 diabetes. To do this the Flagstaff, AZ-based company is investing in PhysioLogic Devices, a startup developing an implantable intraperitoneal insulin delivery system. The investment is set to provide supplemental funding to allow Elkton, MD-based PhysioLogic to reduce key challenges associated with implantable micropumps and actuators and enable the startup's development goals for the upcoming years. An essential part of the system that PhysioLogic is developing is an implanted catheter for intraperitoneal insulin ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
This study demonstrates for the first time that senescent cells secrete functional LTs, significantly contributing to the LTs pool known to cause or exacerbate idiopathic pulmonary fibrosis. Against Senolytics https://www.fightaging.org/archives/2019/11/against-senolytics/ There is no consensus in science that is so strong as to have no heretics. So here we have an interview with a naysayer on the matter of senolytic treatments, who argues that the loss of senescent cells in aged tissues will cause more harm to long-term health than the damage they will do by remaining. To be clear, I think this to be a ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusion: In a representative Brazilian population of T1DM patients, those with IDAA1c ≤ 9 presented a lower frequency of MC, as well as fewer episodes of hypoglycemia, in the month prior to the analysis.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Type 1 | Endocrinology | International Medicine & Public Health | Stem Cell Therapy | Stem Cells | USA Health